Abstract
In the present study, we selected in vitro populations of Leishmania Viannia guyanensis, L.V. braziliensis, L. Leishmania amazonensis and L.L. infantum chagasi that were resistant to potassium antimony tartrate (SbIII). The resistance index of these populations varied from 4- to 20-fold higher than that of their wild-type counterparts. To evaluate the stability of the resistance phenotype, these four resistant populations were passaged 37 to 47 times in a culture medium without SbIII. No change was observed in the resistance indexes of L.V. guyanensis (19-fold) and L.L. infantum chagasi (4-fold). In contrast, a decrease in the resistance index was observed for L.V. braziliensis (from 20- to 10-fold) and L.L. amazonensis (from 6- to 3-fold). None of the antimony-resistant populations exhibited cross-resistance to amphotericin B and miltefosine. However, the resistant populations of L.V. braziliensis, L.L. amazonensis and L.L. infantum chagasi were also resistant to paromomycin. A drastic reduction was observed in the infectivity in mice for the resistant L.V. guyanensis, L.L. amazonensis and L.V. braziliensis populations. The SbIII-resistant phenotype of L.V. braziliensis was stable after one passage in mice. Although the protocol of induction was the same, the SbIII-resistant populations showed different degrees of tolerance, stability, infectivity in mice and cross-resistance to antileishmanial drugs, depending on the Leishmania species.
Abbreviations
- SbIII:
-
potassium antimony tartrate
- WTS:
-
wild-type susceptible
- SbR:
-
SbIII-resistant
- Lg:
-
L.V. guyanensis
- Lb:
-
L.V. braziliensis
- La:
-
L.L. amazonensis
- Lc:
-
L.L. infantum chagasi
References
Al-Mohammed HI, Chance ML, Bates PA (2005) Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana. Antimicrob Agents Chemother 49(8):3274–3280
Anacleto C, Abdo MC, Ferreira AV, Murta SM, Romanha AJ, Fernandes AP, Moreira ES (2003) Structural and functional analysis of an amplification containing a PGPA gene in a glucantime-resistant Leishmania (Viannia) guyanensis cell line. Parasitol Res 90(2):110–118
Arana FE, Pérez-Victoria JM, Repetto Y, Morello A, Castanys S, Gamarro F (1998) Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica. Biochem Pharmacol 56:1201–1208
Basselin M, Robert-Gero M (1998) Alterations in membrane fluidity, lipid metabolism, mitochondrial activity, and lipophosphoglycan expression in pentamidine-resistant Leishmania. Parasitol Res 84(1):78–83
Berman JD, Ksionski G, Chapman WL, Waits VB, Hanson WL (1992) Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother 36:1978–1980
Bories C, Cojean S, Huteau F, Loiseau PM (2008) Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomed Pharmacother 62:164–167
Brochu C, Wang J, Roy G, Messier N, Wang XY, Saravia NG, Ouellette M (2003) Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother 47:3073–3079
Centers for Disease Control and Prevention (2009) Available from: www.dpd.cdc.gov/dpdx/HTML/Leishmaniasis.htm. Reviewed November 14
Croft SL (2001) Monitoring drug resistance in leishmaniasis. Trop Med Int Health 6(11):899–905
Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111–126
Cunningham ML, Titus RG, Turco SJ, Beverley SM (2001) Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin. Science 292:285–287
Davidson RN, Croft SL, Scott A, Maini M, Moody AH, Bryceson AD (1991) Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337:1061–1062
de Roode JC, Culleton R, Bell AS, Read AF (2004) Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections. Malar J 14:33
Decuypere S, Rijal S, Yardley V, De Doncker S, Laurent T, Khanal B, Chappuis F, Dujardin JC (2005) Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother 49(11):4616–4621
Dey S, Papadopoulou B, Haimeur A, Roy G, Grondin K, Dou D, Rosen BP, Ouellette M (1994) High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system. Mol Biochem Parasitol 67(1):49–57
El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, Saravia NG, Papadopoulou B, Légaré D, Ouellette M (2005) Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother 49:1988–1993
García N, Figarella K, Mendoza-León A, Ponte-Sucre A (2000) Changes in the infectivity, pyruvate kinase activity, acid phosphatase activity and P-glycoprotein expression in glibenclamide-resistant Leishmania mexicana. Parasitol Res 86(11):899–904
Gazola KC, Ferreira AV, Anacleto C, Michalick MS, Andrade AF, Moreira ES (2001) Cell surface carbohydrates and in vivo infectivity of glucantime-sensitive and resistant Leishmania (Viannia) guyanensis cell lines. Parasitol Res 87(11):935–940
Geretti AM (2005) The clinical significance of viral fitness. J HIV Ther 10(1):6–10
Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279(30):31010–31017
Haimeur A, Brochu C, Genest P, Papadopoulou B, Ouellette M (2000) Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol Biochem Parasitol 108:131–135
Hayward R, Saliba KJ, Kirk K (2005) pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum. Mol Microbiol 55:1285–1295
Herwaldt BL (1999) Leishmaniasis. Lancet 354:1191–1199
Jhingran A, Chawla B, Saxena S, Barrett MP, Madhubala R (2009) Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 164:111–117
Lenski RE (1998) Bacterial evolution and the cost of antibiotic resistance. Int Microbiol 1(4):265–270
Lipoldova M, Demant P (2006) Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nat Rev Genet 7:294–305
Lira R, Mendez S, Carrera L, Jaffe C, Neva F, Sacks D (1998) Leishmania tropica: the identification and purification of metacyclic promastigotes and use in establishing mouse and hamster models of cutaneous and visceral disease. Exp Parasitol 89:331–342
Ma C, Tran J, Li C, Ganesan L, Wood D, Morrissette N (2008) Secondary mutations correct fitness defects in Toxoplasma gondii with dinitroaniline resistance mutations. Genetics 180(2):845–856
Marquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M (2005) Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol 57(6):1690–1699
Marsden PD (1986) Mucosal leishmaniasis (‘espundia’ Escomel, 1911). Trans R Soc Trop Med Hyg 80:859–876
Mbongo N, Loiseau PM, Billion MA, Robert-Gero M (1998) Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother 42:352–357
Moreira ES, Anacleto C, Petrillo-Peixoto ML (1998) Effect of glucantime on field and patient isolates of New World Leishmania: use of growth parameters of promastigotes to assess antimony susceptibility. Parasitol Res 84:720–726
Natera S, Machuca C, Padrón-Nieves M, Romero A, Díaz E, Ponte-Sucre A (2007) Leishmania spp.: proficiency of drug-resistant parasites. Int J Antimicrob Agents 29(6):637–642
Ouellette M, Drummelsmith J, Papadopoulou B (2004) Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7(4–5):257–266
Romero GA, Guerra MV, Paes MG, Macêdo VO (2001) Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 65:456–465
Seifert K, Matu S, Javier Pérez-Victoria F, Castanys S, Gamarro F, Croft SL (2003) Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22:380–387
Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A, Lemesre JL (1998) Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 42:3097–3102
Sereno D, Holzmuller P, Lemesre JL (2000) Efficacy of second line drugs on antimonyl-resistant amastigotes of Leishmania infantum. Acta Trop 74:25–31
Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D (2001) Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem 276:3971–3976
Shaw JJ (2006) Further thoughts on the use of the name Leishmania (Leishmania) infantum chagasi for the aetiological agent of American visceral leishmaniasis. Mem Inst Oswaldo Cruz 101:577–579
Shimony O, Jaffe CL (2008) Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods 75(2):196–200
Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6:849–854
Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31:1104–1107
Thakur CP, Thakur S, Narayan S, Sinha A (2008) Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate. Indian J Med Res 127:582–588
Walliker D, Hunt P, Babiker H (2005) Fitness of drug-resistant malaria parasites. Acta Trop 94:251–259, Review
Wyllie S, Cunningham ML, Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279:39925–39932
Acknowledgements
The authors wish to thank Dr. Lucas Antônio Miranda Ferreira (UFMG/Brazil) for providing the miltefosine. This investigation received financial support from the following agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) and UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liarte, D.B., Murta, S.M.F. Selection and phenotype characterization of potassium antimony tartrate-resistant populations of four New World Leishmania species. Parasitol Res 107, 205–212 (2010). https://doi.org/10.1007/s00436-010-1852-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-010-1852-8